Peptide LibraryHuman study PLS-00239
A Phase 1b Study of Thymosin Beta 4 in Healthy Volunteers
Version 1 · published November 8, 2026 · evidence through November 8, 2026 · research snapshot 2026.1.1 · methodology ev-1 · Automated assessment by AI (claude-opus-5-5 and claude-sonnet-5-5), not reviewed by a person.
Reports of this study
Every publication, registration and abstract describing this one study. Participants are counted once.
- A Phase 1b Study of Thymosin Beta 4 in Healthy Volunteersregistry entry · NCT04555850 (COMPLETED, no results posted, planned enrollment 30)
Design and participants
- Design
- Other design
- Population
- Healthy volunteers
- Conditions
- Healthy
- Planned enrollment (registry)
- 30
- Enrolled
- 30
- Randomized
- Not reported
- Completed follow-up
- Not reported
Intervention and comparator
What each group received. Related peptides, analogs and combinations are never treated as the compound itself.
- Recombinant Human Thymosin β4 (rh-Tβ4) (intervention) · thymosin-beta-4 · Recombinant human thymosin β4 (rh-β4), as listed in the registry interventions · Not reported assigned
- Placebo (comparator) · Placebo, as listed in the registry interventions · placebo · Not reported assigned
What the authors reported
As stated in the sources. This is the authors’ account, not Peptide Library’s assessment.
Adverse events
None reported. That is not evidence of safety, and how safety was monitored isn’t described.
Peptide Library’s assessment
An automated assessment, made by AI separately from the authors’ conclusions and not reviewed by a person. How risk of bias is assessed.
Limitations
- other: The registry fields do not state the allocation method or masking, so it is unknown whether participants were randomized to the placebo comparison.
- abstract only: The only source is the ClinicalTrials.gov registration. There is no publication or abstract, and outcome measures are not listed in the record.
- inappropriate population: Healthy volunteers were enrolled, so the study cannot speak to efficacy in any disease such as dry eye.
- small or imprecise: Actual enrollment is only 30 participants in a Phase 1b study, which limits detection of uncommon adverse events.
No risk-of-bias assessment has been published for this study’s results.
Claims this study informs
- Improves dry eye signs and symptoms: not eligible (wrong population) for “Ocular discomfort and corneal staining”
- Is safe for human administration: not eligible (insufficient data) for “Adverse events, serious adverse events and discontinuations”
Where each value comes from
- arms: NCT NCT04555850, registry (interventions field) · extracted by AI (automated, not verified by a person)
- design: NCT NCT04555850, registry (phases and study_type fields) · extracted by AI (automated, not verified by a person)
- limitations: NCT NCT04555850, registry (status and has_results fields) · extracted by AI (automated, not verified by a person)
- participants: NCT NCT04555850, registry (enrollment and enrollment_type fields) · extracted by AI (automated, not verified by a person)
- population: NCT NCT04555850, registry (conditions field) · extracted by AI (automated, not verified by a person)
Version 1 · published November 8, 2026 · evidence through November 8, 2026 · research snapshot 2026.1.1 · methodology ev-1 · Automated assessment by AI (claude-opus-5-5 and claude-sonnet-5-5), not reviewed by a person.
These assessments describe published research. Records marked automated were produced by AI under the published methodology and have not been reviewed by a person; they can contain errors. None of this is medical advice, not a statement about any product’s safety for human use, and not a regulatory approval. Peptide Library’s vendor and partner relationships play no part in them (editorial independence).